Welcome to our dedicated page for Medtronic SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medtronic plc filings document material events, capital structure, registered securities, governance matters, and operating and financial disclosures for a medical-device company organized in Ireland. The 8-K record identifies MDT ordinary shares and multiple series of senior notes listed on the New York Stock Exchange, alongside current reports used for company events and financial-result communications.
The filing record also includes exchange and registration status for debt securities, including a Form 25 notice tied to removal from listing and registration of a guarantor class of senior notes. These disclosures frame Medtronic's public-company obligations around equity, debt instruments, material agreements, and regulatory or clinical developments.
Medtronic PLC reports that Vanguard Capital Management beneficially owned 96,424,044 shares of Common Stock, representing 7.51% of the class as of 03/31/2026. The filing states Vanguard has sole power to dispose of 96,424,044 shares and sole voting power for 13,090,211 shares. The disclosure attributes holdings to Vanguard Capital Management LLC and specified affiliates and was signed on 04/28/2026.
Medtronic plc reported that an unauthorized third party accessed data in certain corporate IT systems. After discovering the issue, the company contained the incident, activated its response protocols, and brought in external cybersecurity experts to investigate and remediate.
Medtronic states it has not identified any impact on its products, patient safety, customer connections, manufacturing and distribution operations, financial reporting systems, or its ability to meet patient needs. Based on current findings, it does not expect a material impact on its business or financial results. The company is assessing whether personal information was accessed and will notify and support affected individuals as needed.
The Vanguard Group filed Amendment No. 10 to a Schedule 13G/A regarding Medtronic PLC common stock, reporting 0 shares beneficially owned and 0% of the class. The filing explains an internal realignment effective January 12, 2026 under SEC Release No. 34-39538 that caused certain Vanguard subsidiaries or divisions to report holdings separately.
The statement is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Medtronic plc reported that its subsidiary MiniMed Group received earlier-than-expected U.S. FDA clearance for the MiniMed Flex, a next-generation, smartphone-controlled insulin pump. The product’s research and development was partly funded by Blackstone Life Sciences under a deal that entitles Blackstone to mid-to-high single digit royalties or specified minimum payments for two years after U.S. approval and launch.
MiniMed expects to record a one-time charge of $157 million in Medtronic’s fourth quarter of fiscal 2026 for future payments to Blackstone, with an estimated $0.08 per share impact based on Medtronic’s 90% MiniMed ownership. Separately, the recent IPO of 10% of MiniMed is expected to dilute Medtronic shareholders by about $0.04 per share in that quarter.
As a result, Medtronic now guides full-year fiscal 2026 non-GAAP EPS to $5.50–$5.54, reduced from the prior $5.62–$5.66 range. Guidance for fiscal 2027 remains unchanged at high single-digit EPS growth and is based on the earlier, higher EPS baseline before these MiniMed-related items.
Medtronic plc filed a shelf registration under Form S-3 to permit the periodic offering of debt securities by Medtronic Global Holdings S.C.A. and Medtronic, Inc., to be offered "from time to time after this registration statement becomes effective."
The prospectus states debt issued by each issuer will be fully and unconditionally guaranteed on a joint and several basis by the other group members named, and that specific terms, amounts and distribution methods will be provided in prospectus supplements.
Medtronic plc filed an initial ownership report for MiniMed Group, Inc., stating indirect beneficial ownership of 252,813,348 shares of MiniMed common stock. This Form 3 does not report new share purchases or sales, but formally records Medtronic as a more than 10% owner.
Medtronic plc filed an initial ownership report for MiniMed Group, Inc., stating indirect beneficial ownership of 252,813,348 shares of MiniMed common stock. This Form 3 does not report new share purchases or sales, but formally records Medtronic as a more than 10% owner.
Medtronic plc executive vice president and chief financial officer Thierry Pieton reported a tax-related share disposition tied to equity compensation. On the transaction date, 2,976 ordinary shares were withheld at a price of $96.71 per share to cover taxes upon the vesting of previously granted restricted stock units. After this withholding, Pieton directly held 37,574 Medtronic ordinary shares, which total includes 592 shares acquired through dividend reinvestment since his prior report.
Medtronic plc executive vice president and chief financial officer Thierry Pieton reported a tax-related share disposition tied to equity compensation. On the transaction date, 2,976 ordinary shares were withheld at a price of $96.71 per share to cover taxes upon the vesting of previously granted restricted stock units. After this withholding, Pieton directly held 37,574 Medtronic ordinary shares, which total includes 592 shares acquired through dividend reinvestment since his prior report.
Medtronic plc executive Harry Skip Kiil reported mixed equity transactions involving stock options and ordinary shares. On February 19, 2026, he exercised multiple stock options (rights to buy), converting them into ordinary shares at exercise prices reflected as $0.0000 per option in the derivative rows.
On the same date, he conducted several open-market sales of ordinary shares coded as "S," totaling 52,524 shares sold according to the transaction summary. Sale prices for these transactions include individual entries around $97.66 to $97.86, with a footnote stating a weighted average sale price and an actual range from $97.60 to $97.775.
Following these exercises and sales, his directly held ordinary share balance shown in the final row is 32,768 shares. A footnote also notes that this total includes 239 shares acquired through dividend reinvestment since his prior report.
Medtronic plc Chief Accounting Officer Denise L. Blomquist reported a bona fide gift of 340 Ordinary Shares of Medtronic on February 20, 2026. The gift was reported at a price of $0.00 per share, indicating no consideration was received for the transfer.
Following this charitable or personal gift transaction, Blomquist’s directly held stake stands at 11,966 Ordinary Shares of Medtronic. The filing reflects a disposition of shares through gifting rather than an open-market sale or purchase.
Medtronic plc reported fiscal Q3 2026 net sales of $9.0 billion, up from $8.3 billion a year earlier, driven by growth across Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. Operating profit declined to $1.5 billion, and net income attributable to Medtronic fell to $1.1 billion, with diluted EPS at $0.89 versus $1.01.
For the first nine months, revenue reached $26.6 billion, up from $24.6 billion, while net income was roughly flat at $3.6 billion and diluted EPS was $2.76. Strong operating cash flow of $4.8 billion funded $2.7 billion in dividends and $0.6 billion of share repurchases, even as long‑term debt rose to $27.9 billion.
The company is preparing to separate its Diabetes business into MiniMed, an independent public company, and has launched a restructuring program expected to cost $300–$500 million through fiscal 2029. Medtronic also recorded higher restructuring and certain litigation charges and continued using derivative and funding arrangements to manage currency, interest rate, and development risks.